Haemadipsa Oligomeric Decorsin
First oligomeric decorsin-class platelet aggregation inhibitor identified in a haemadipsid leech (Müller 2024) — weak inhibitor in functional assays.
Praeklinisch / mechanistischLast updated: 2026-05-27 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- First oligomeric decorsin-class platelet aggregation inhibitor identified in a haemadipsid leech (Müller 2024) — weak inhibitor in functional assays.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
The oligomeric decorsin's weak in vitro platelet inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 12,000 Da
- Source species
- Haemadipsa interrupta
- Discovered
- 2024 · Müller C et al.
Biological Targets
- → platelet aggregation (weak in vitro inhibition)
Key Citations
- Müller C et al. (2024), Parasitol Res · PMID 39570434
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.